The world's first international patient to receive Satri-cel, the newly approved CAR-T therapy for solid tumors, has successfully completed leukapheresis at Jiahui International Cancer Center (JICC) in Shanghai, marking a historic milestone in making China's latest oncology innovations accessible to patients worldwide.
Currently approved exclusively in China, Satri-cel is the world's first CAR-T therapy for the treatment of a solid tumor. As one of China's leading international cancer centers, JICC is uniquely positioned to connect eligible patients from around the world with this groundbreaking treatment. Having already cared for CAR-T patients from across the globe, the center continues to play an important role in making China's most advanced cancer therapies accessible to international patients.
Patient Background
Josh, a 59-year-old man from New Zealand, was diagnosed with advanced gastroduodenal cancer. Despite undergoing standard treatment in his home country, his disease continued to progress.
Seeking Innovative Treatment
As conventional treatment options became increasingly limited, the patient began exploring innovative therapies available internationally. His search ultimately led him to China and Jiahui International Cancer Center, which he selected for its multidisciplinary oncology platform, comprehensive hospital capabilities and extensive experience in delivering advanced CAR-T therapies.
Pre-Treatment Testing and Evaluation
Following guidance from JICC, the patient first underwent biomarker testing in New Zealand. The results confirmed Claudin 18.2 positivity and HER2 negativity, meeting the eligibility criteria for Satri-cel therapy.
In late June, he travelled to Shanghai with his wife to begin treatment. After completing PET-CT imaging, multidisciplinary evaluation and treatment planning at JICC, he successfully underwent leukapheresis. His CAR-T cells have now entered the manufacturing process, with reinfusion planned approximately three weeks later.
Expert Statement
Dr. Linli Xuan, Chief of Medical Oncology at Jiahui International Cancer Center, said:
"The approval of Satri-cel represents a historic milestone not only for patients with advanced gastric cancer, but also for the global field of oncology. We are honoured that the world's first international patient has chosen Jiahui International Cancer Center to receive this groundbreaking therapy. As innovative cancer treatments developed in China continue to gain international recognition, we are seeing growing interest from patients around the world seeking access to these advances. Our mission extends beyond providing access to innovative therapies—we are committed to ensuring that every patient receives seamless, multidisciplinary and patient-centred care throughout every stage of their treatment journey."
Comprehensive Oncology Services at JICC
Jiahui International Cancer Center provides comprehensive oncology services spanning medical oncology, surgical oncology, radiation oncology, precision medicine and advanced cellular therapies. Through its multidisciplinary care model and dedicated International Patient Office, JICC supports patients worldwide with medical record review, specialist consultations, multilingual coordination, treatment planning, logistics assistance and ongoing follow-up care.
Commitment to Global Patient Access
As global awareness of China's rapidly evolving oncology innovation ecosystem continues to grow, JICC remains committed to serving as a bridge between patients worldwide and the latest advances in cancer treatment, ensuring that eligible patients can access groundbreaking therapies in a safe, coordinated and patient-centered environment.
Contact Jiahui's International Office:
Email: internationaloffice@jiahui.com
WhatsApp: +852 4619 1904
WeChat: Jiahui-GSN
